Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Satellos Bioscience Inc Com V.ICO


Primary Symbol: ICOTF

iCo Therapeutics Inc is a Canada based biotechnology company. It is involved in the Research and development of ophthalmic indications. The company identifies, develops, and commercialize drug candidates with clinical history, and re-doses, reformulates and develops these drug candidates to treat sight and life-threatening diseases. Its in-licensed assets are iCo-008 and the Oral AmpB Delivery System. iCo-008 is a human monoclonal antibody targeting eotaxin-1 that acts as a messenger between...


GREY:ICOTF - Post by User

Bullboard Posts
Post by mining4dollarson Sep 06, 2013 3:03pm
234 Views
Post# 21723519

Re. Cantech letter

Re. Cantech letter
Good find. 

The past two weeks interest has picked up dramatically in ICO.  Over 2m shares traded and being bought by a diverse group (Jordan, RBC, TD and Anonymous doing the heavy lifting) of buyers.

Of note, as per their first clinical update on the iDEAL 007 trial in January, 149 patients had initiated dosing at that time.  As we are now in September, all 149 of those patients would be completely through the dosing stage(8 months in length), which would work out to roughly 75% of the total trial participants.   The primary endpoint of the iDEAL trial is a change in visual acuity from baseline to month eight, meaning you better believe that the evidence is now mounting in a VERY meaningful way and we are getting CLOSE!

My guess is we breach the mid $.50's next week and by  the end of October we pass our previous highs.  We are too advanced at this stage not to be on some very influential radars and we are slowly hitting a critical mass in terms of getting an explosive rally started.

Bullboard Posts